ADL5859 HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526705

CAS#: 850173-95-4 (ADL 5859 HCl)

Description: ADL5859 is a potent, orally bioavailable delta opioid receptor agonist for the treatment of pain ( Ki of 0.8 nM ). ADL5859 agonizes δ-opioid receptor with a 1000-fold selectivity than µ- or κ-opioid receptor with Ki of 32 nM and 37 nM, respectively.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 3250
Size
Price

25mg
USD 250
200mg
USD 1250
2g
USD 4250
Size
Price

50mg
USD 450
500mg
USD 1950
5g
Ask price

ADL5859 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 526705
Name: ADL5859 HCl
CAS#: 850173-95-4 (ADL 5859 HCl)
Chemical Formula: C24H29ClN2O3
Exact Mass:
Molecular Weight: 428.957
Elemental Analysis: C, 67.20; H, 6.81; Cl, 8.26; N, 6.53; O, 11.19


Related CAS #: 850305-06-5 (ADL 5859 free base)  

Synonym: ADL5859; ADL-5859; ADL 5859; ADL5859 HCl.

IUPAC/Chemical Name: N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidin]-4-yl)benzamide hydrochloride

InChi Key: ZFNLSWREIULTDO-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21;/h5-11,16,25,27H,3-4,12-15H2,1-2H3;1H

SMILES Code: O=C(N(CC)CC)C1=CC=C(C2=CC3(CCNCC3)OC4=CC=CC(O)=C24)C=C1.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
850173-95-4 (ADL5859 HCl)
850305-06-5 ( ADL5859 free base)


References

1: Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY. Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol. 2016 Jun 15;781:53-9. doi: 10.1016/j.ejphar.2016.03.061. Epub 2016 Apr 1. PubMed PMID: 27044434.

2: Chung PC, Boehrer A, Stephan A, Matifas A, Scherrer G, Darcq E, Befort K, Kieffer BL. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res. 2015 Feb 1;278:429-34. doi: 10.1016/j.bbr.2014.10.029. Epub 2014 Oct 30. PubMed PMID: 25447299; PubMed Central PMCID: PMC4382405.

3: Nozaki C, Nagase H, Nemoto T, Matifas A, Kieffer BL, Gaveriaux-Ruff C. In vivo properties of KNT-127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice. Br J Pharmacol. 2014 Dec;171(23):5376-86. doi: 10.1111/bph.12852. PubMed PMID: 25048778; PubMed Central PMCID: PMC4294046.

4: van Rijn RM, Harvey JH, Brissett DI, DeFriel JN, Whistler JL. Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. J Pharmacol Exp Ther. 2013 Jan;344(1):179-88. doi: 10.1124/jpet.112.198655. Epub 2012 Oct 24. PubMed PMID: 23097213; PubMed Central PMCID: PMC3533407.

5: Nozaki C, Le Bourdonnec B, Reiss D, Windh RT, Little PJ, Dolle RE, Kieffer BL, Gavériaux-Ruff C. δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther. 2012 Sep;342(3):799-807. doi: 10.1124/jpet.111.188987. Epub 2012 Jun 13. PubMed PMID: 22700431; PubMed Central PMCID: PMC3422521.

6: Le Bourdonnec B, Windh RT, Leister LK, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). J Med Chem. 2009 Sep 24;52(18):5685-702. doi: 10.1021/jm900773n. PubMed PMID: 19694468.

7: Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem. 2008 Oct 9;51(19):5893-6. doi: 10.1021/jm8008986. Epub 2008 Sep 13. PubMed PMID: 18788723.